Hospital General Universitario Gregorio Marañón

ETOPOSIDE FOR PRIMARY HLH - BETTER THAN ITS REPUTATION (2023) Lehmberg K, Ledig S, Wustrau K, Kontny U, Westphal S, Hundsdoerfer P, Jorch N, et al. Conference contribution A Quality Assessment of the ARM-Net Registry Design and Data Collection. (2023) Hageman IC, van der Steeg HJ, Jenetzky E, Trajanovska M, King SK, de Blaauw I, van Rooij IA, et al. Journal article Pharmacological and dietary-supplement treatments for autism spectrum disorder: a systematic review and network meta-analysis (2022) Siafis S, Ciray O, Wu H, Schneider-Thoma J, Bighelli I, Krause M, Rodolico A, et al. Journal article CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Adults with B-Cell Acute Lymphoblastic Leukemia (B-ALL): A Large Real-World Series from Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT) (2022) Brissot E, Peczynski C, Labopin M, Lussana F, Hough R, Kuball J, Rösler W, et al. Conference contribution Alnuctamab (ALNUC; BMS-986349; CC-93269), a B-Cell Maturation Antigen (BCMA) x CD3 T-Cell Engager (TCE), in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from a Phase 1 First-in-Human Clinical Study (2022) Wong SW, Bar N, Paris L, Hofmeister CC, Hansson M, Santoro A, Mateos MV, et al. Conference contribution Effectiveness and safety of tocilizumab in patients with systemic sclerosis: a propensity score matched controlled observational study of the EUSTAR cohort (2022) Kuster S, Jordan S, Elhai M, Held U, Steigmiller K, Bruni C, Cacciapaglia F, et al. Journal article HLA-mismatched unrelated donor transplantation with post-transplant cyclophosphamide versus HLA-haploidentical transplantation in patients with active acute myeloid leukemia (2022) Baron F, Labopin M, Tischer J, Ciceri F, Raiola AM, Blaise D, Sica S, et al. Conference contribution Global Circumferential and Radial Strain Among Patients With Immune Checkpoint Inhibitor Myocarditis (2022) Quinaglia T, Gongora C, Awadalla M, Hassan MZ, Zafar A, Drobni ZD, Mahmood SS, et al. Journal article Abatacept Significantly Reduces Subclinical Inflammation During Treatment (6 Months), This Persists After Discontinuation (12 Months), Resulting in a Delay in the Clinical Development of RA in Patients at Risk of RA (The ARIAA Study) (2022) Rech J, Kleyer A, Ostergaard M, Hagen M, Mendez LV, Tascilar K, Krönke G, et al. Conference contribution How Well Does Ultrasound-assessed Synovitis in Reduced Joint Sets Predict the Response to Secukinumab in Patients with Active Psoriatic Arthritis and Inadequate Response to Conventional DMARDs? - Exploratory Results from a Phase 3b Study (2022) D'Agostino MA, Conaghan PG, Gaillez C, Naredo E, Mandl P, Carron P, Senolt L, et al. Conference contribution